Md Clinical

Hallandale, Florida 3309

0 studies enrolling now · 91 studies all time

What they study most

Acute Migraine, Alzheimer Disease, Alzheimer's Disease, Attention Deficit Hyperactivity Disorder, Aura, Behavioral Variant Frontotemporal Dementia, Bipolar Disorder, Central Nervous System Diseases, Chronic Nonmalignant and Nonneuropathic Pain, Chronic Pain, Cognition, Depression

Studies at this site

• Safety and Efficacy of TRx0237 in Subjects With Alzheimer's Disease Followed by Open-Label Treatment — Completed
• A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2) — Running, not enrolling
• A Long Term Safety Study of ND0612 Administered as a Continuous SC Infusion in Advanced Parkinson's Disease — Running, not enrolling
• This Study Tests Whether BI 409306 Prevents Patients With Schizophrenia From Becoming Worse. This Study Looks at How Well Patients Tolerate BI 409306 and How Effective it is Over 6 Months — Stopped early
• A Study of LY3372993 in Participants With Alzheimer's Disease (AD) and Healthy Participants — Completed
• Tetra PICASSO AD Trial: Study to Evaluate Effects of BPN14770 in Early Alzheimer's Subjects — Completed
• Study of the Efficacy and Safety of Lemborexant in Subjects 55 Years and Older With Insomnia Disorder (SUNRISE 1) — Completed
• A Study of the Safety and Tolerability of ASP0777 in Subjects With Alzheimer's Disease (AD) Taking a Stable Dose of Donepezil — Completed
• Safety and Efficacy of Piromelatine in Mild Alzheimer's Disease Patients (ReCOGNITION) — Completed
• Study of AGB101 in Mild Cognitive Impairment Due to Alzheimer's Disease — Completed
• A Study of a Single Intravenous Infusion Dose of TAK-925 in Participants With Idiopathic Hypersomnia — Completed
• Acute Treatment Trial in Adult Subjects With Migraines — Completed
• A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of PF-06649751 in Subjects With Idiopathic Parkinson's Disease — Completed
• PF-06669571 In Subjects With Idiopathic Parkinson's Disease — Completed
• A Study to Evaluate the Safety of STS101 in the Acute Treatment of Migraine — Completed
• A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate STS101 in the Acute Treatment of Migraine — Completed
• Open-Label Study of Leuco-methylthioninium Bis(Hydromethanesulfonate) (LMTM) in Subjects With Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia (bvFTD) — Stopped early
• A Study of Weekly Subcutaneous Injections of SER-214 in Subjects With Parkinson's Disease (PD), to Determine the Safety, Tolerability and Pharmacokinetic (PK) Profile of SER-214 — Status unconfirmed
• Posiphen® Dose-Finding, Biomarker Study in Early Alzheimer's and Parkinson's Patients — Completed
• GAIN Trial: Phase 2/3 Study of COR388 in Subjects With Alzheimer's Disease — Completed
• Trial in Adult Subjects With Acute Migraines — Completed
• Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD) Who Have Had an Inadequate Response to Antidepressants Alone — Completed
• A Study to Assess the Safety of GRF6021 Infusions in Subjects With Parkinson's Disease and Cognitive Impairment — Completed
• AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext — Completed
• Study to Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine — Completed
• A Study to Evaluate Next-Dose Transition From Zolpidem to Lemborexant (LEM) for the Treatment of Insomnia — Completed
• A Study Of The Analgesic (Pain-Relief) Effects Of Tanezumab In Adult Patients With Diabetic Peripheral Neuropathy — Stopped early
• A Randomized Study to Assess the Safety of GRF6019 Infusions in Subjects With Mild to Moderate Alzheimer's Disease — Completed
• Effect Of Pregabalin Treatment In Patients With Diabetic Nerve Pain Who Currently Use A Non-Steroid Anti-Inflammatory Drug (NSAID) For Another Pain — Completed
• Study Of Pregabalin (Lyrica) In Patients With Painful Diabetic Peripheral Neuropathy — Completed
• Vortioxetine, 5, 10, and 20 mg, Relapse Prevention Study in Adults With Major Depressive Disorder (MDD) — Completed
• Open-label Long Term (52 Weeks) Safety and Tolerability of Agomelatine Sublingual Tablets in Major Depressive Disorder (MDD) — Stopped early
• A Study Of PF-04447943 Compared To Placebo In Subjects With Mild To Moderate Alzheimer's Disease — Completed
• A Brief Study To Evaluate The Safety, Tolerability, And Blood Levels Of Multiple Doses Of PF-044467943 Or Placebo In Combination With Donepezil In Subjects With Mild To Moderate Alzheimer's Disease — Completed
• BI 425809 in Patients With Cognitive Impairment Due to Alzheimer's Disease. — Completed
• A Study of Bryostatin in Moderately Severe to Severe Alzheimer's Disease Subjects Not On Memantine — Completed
• An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine — Completed
• A Cardiac Safety Study of an Investigational Drug to See How if Affects the Heart in People With Parkinson's Disease Complicated by Motor Fluctuations "OFF" Episodes — Completed
• Long-term Safety Study of Rapastinel as Adjunctive Therapy in Patients With Major Depressive Disorder — Completed
• Study of TAK-925 in Participants With Obstructive Sleep Apnea (OSA) Who Are Experiencing Excessive Daytime Sleepiness (EDS) Despite Adequate Use of Continuous Positive Airway Pressure (CPAP) — Completed
• A Multiple Ascending Dose Study to Evaluate Safety and Tolerability of BFKB8488A in Participants With Type 2 Diabetes Mellitus and Participants With Non-Alcoholic Fatty Liver Disease — Completed
• Single-Ascending-Dose Study of BIIB076 in Healthy Volunteers and Participants With Alzheimer's Disease — Completed
• Long-term Safety of Once-daily Hydrocodone Bitartrate (HYD) Tablets For Moderate to Severe Chronic Nonmalignant and Nonneuropathic Pain. Includes a 24-week Extension Period. — Completed
• A Study of Rapastinel as Adjunctive Therapy in the Prevention of Relapse in Patients With Major Depressive Disorder — Completed
• A Phase 3 Study of Tanezumab for Chronic Low Back Pain — Completed
• A 4-Week Study of the Safety, Efficacy, and Pharmacokinetics of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate Hydrochloride] in Subjects With Parkinson's Disease and Excessive Sleepiness — Completed
• Lasmiditan Compared to Placebo in the Acute Treatment of Migraine: — Completed
• A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-01) — Completed
• Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo — Stopped early
• "Twelve-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in OSA" — Completed